(4S,5R)-3-Benzoyl-2,2-Dimethyl-4-Phenyloxazolidine-5-Carboxylic Acid: Precision for Modern Synthesis

Real-World Reliability From the Plant Floor

Watching a reaction transform with clarity in the flask has always meant more to us than a number on a sheet. (4S,5R)-3-Benzoyl-2,2-Dimethyl-4-Phenyloxazolidine-5-Carboxylic Acid grew from that patient scrutiny, from what teams in synthesis actually encounter when moving from stepwise trials to multi-kilo runs. A rigorous chiral intermediate, engineered not for shelf-appeal, but for mapping out reliable stereochemistry in demanding projects—this compound answers the most persistent obstacles with real-world dependability. Across campaigns in API synthesis and custom chemistry, it offers the kind of repeatability that sidesteps late-stage surprises.

Focused Design in Structure and Application

We leaned heavily on isomeric purity when finalizing this molecule’s production pathway. Both the four- and five-position ring stereochemistry—locked as (4S,5R)—give it utility well beyond structurally similar oxazolidines. Previous iterations or off-the-shelf options couldn’t consistently control unwanted epimers during scale-up, which led to inflated purification times and risk of yield loss. Our process starts with chiral building blocks that never stray out of the desired optical rotation.

There’s a palpable shift when you have single-enantiomer precision in the bench bottle—yield profiles stay on target, peak overlap falls away in chromatography, and follow-on conversions require less work to realize downstream complexity. We see these differences most sharply with peptide coupling, especially for designer amino acid scaffolds and peptidomimetic research. The ring system resists racemization, outpacing older routes that force a cumbersome protect-deprotect routine.

Process Consistency and Specification

Chemistry never forgives loose controls, so everything from solvent shifts in the crystallization phase to temperature gradients during benzoylation has seen scrutiny in our operation. Batch analytics confirm optical purity—typically above 99%—backed by tight melting point windows and NMR confirmation. Coloration ranges between off-white to pale yellow, with a fine, crushable crystalline granule. HPLC retention data and MS spectra track for every lot, and critical impurity profiles flag atypical reactivity long before drums head out.

Many clients working with CMO partners have remarked how our material eliminates a headache during handoffs between research and production. The product stays consistent between multi-gram and multi-kilo deliveries, so R&D doesn’t face curveballs halfway through a program. Over time, customers learned that minor slippage in stereochemical control adds costs at every subsequent stage—having the same sample match between lots isn’t a convenience, it’s protection for the whole pipeline.

Where This Compound Earns Its Place

Our customers usually approach us late in project scoping, either after trying catalog sources or walking back from in-house, chiral pool syntheses that drift out of spec. (4S,5R)-3-Benzoyl-2,2-Dimethyl-4-Phenyloxazolidine-5-Carboxylic Acid serves as both a chiral auxiliary and a protected amino acid surrogate in key enantioselective reactions—no two applications seem to use the exact same workflow, yet the consistent need is high-fidelity, chiral backbone introduction.

In peptide bond–forming reactions, especially where the added stability of the oxazolidine ring suppresses unplanned side reactivity, this compound bridges the need for rigidity with predictable downstream cleavage. Peptidomimetic teams—targeting molecules with sp^3 character or unique biophysical properties—almost always swap out older five-membered ring templates for this scaffold, seeing sharper NMR peaks and simpler gradient settings in preparative HPLC. Medicinal chemistry teams, especially with projects on orally available macrocycles, depend on the ready hydrolysis and selective deprotection window.

We’ve seen external partners in asymmetric synthesis use it in aldol-type formations, as a stereocontrolled nucleophile, and in library generation for structure–activity relationship (SAR) studies. Some teams adopted the molecule when their in situ deprotection steps required cleaner removal of both benzoyl and dimethylamino shielding, which our process makes more accessible.

Unlike standard phenyloxazolidines or those lacking the exact carboxylic acid placement, our species drives stereochemistry into the target with minimal epimerization risk. The absence of residual Lewis acid byproducts, confirmed throughout our work-up and washing protocols, grants end-user researchers more flexibility in the protective group orchestration that dominates medicinal chemistry routes.

What Sets This Material Apart

Our experience producing various chiral oxazolidines and their derivatives taught us to pay close attention to purification bottlenecks and final purity pain points. Many competing products come as unresolved mixtures or show significant drift in optical rotation, especially after repeated repackaging or extended logistics. We never rely on external crystallization contractors—the bottleneck always sits within our plant, under our own controls, keeping specifications alive from pilot batches to full-scale campaigns.

Several clients who tried alternate chiral auxiliaries returned frustrated by persistent levels of diastereomers that contaminated their core product. High switching costs and failed re-optimizations dominated their campaigns until they locked in our variant. Seamless analytical handoff between QC teams, as well as transparent sharing of spectral data, gave them confidence to move ahead. They needed alignment not only on purity but on performance during sensitive transformations, such as transition-metal catalysis or reduction protocols where minor contaminants freeze operations.

The enhanced stability of the dioxolane ring structure stands out when compared directly to unmodified analogues. In conditions where related oxazolidines darken or decompose, our product holds its physical integrity and purity, even in long-term storage under appropriate, dry conditions.

Built for Scale and Modern Lab Demands

Controlling heat loads during scale-up moved beyond a theoretical challenge once our operations teams ran repeated pilot syntheses. Initial plant trials proved small deviations in solvent ratios had disproportional effects on yield and color quality. Years of hands-on adjustments led to a granular understanding of phase splits and washing steps that keep side-product formation low. Delivering container-to-container reproducibility meant monitoring every intermediate throughout the campaign—not just the final product.

Clients in process chemistry observe that real challenges often appear at scale. Lab-scale samples from generic vendors look identical under TLC, but introduce uncertainty as soon as multi-gram quantities hit reactors. Our team’s focus on processing integrity means analytical retention times sync with internal reference spectra. For drug development teams, this consistency drives confidence, helping programs advance without stalls from unexpected analytical drifts.

Usage Scenarios and Performance Feedback

In recent campaigns, clients used our compound for fragment coupling in non-peptidic scaffolds. The rigid architecture of the oxazolidine ring transferred both diastereoselectivity and elimination of off-target side products that previously plagued their screening libraries. One medicinal chemistry group moved their macrocyclic intermediate synthesis entirely to this backbone after their catalytic hydrogenation step, which previously failed with competing materials, worked cleanly without unexpected isomerization.

Feedback from academic collaborators highlighted improved yields during stereoselective alkylations. They cited a sharp decrease in side-product formation, and easier monitoring at each step by both TLC and chiral HPLC, compared with less-refined analogues. The carboxylic acid motif not only makes for efficient downstream functionalizations, but also provides a handle for direct attachment to chromatographic resins or further elaboration.

In larger pharma collaborations, our customers dropped re-screening protocols often required for less-controlled chiral pool substances, accelerating their progression from early discovery to process scale. They see improved trust in intermediate consistency, as their own release specifications mirror those from our plant.

Facing Sourcing and Purity Issues in the Market

We receive inquiries from scientists frustrated by batch-to-batch impurity fluctuations in market-standard oxazolidines. Industry sources often lack tight controls on water content and solvent residue, escalating split peaks on analytical runs. By keeping our synthesis and purification under direct supervision, we cleanly separate targeted product from related byproducts each time. Using high-performance filtration and slow, cooling-controlled crystallization, we reach purity markers that downstream users rely on.

Cases where production shifted to generic chiral building blocks saw immediate issues: a rise in chromatography time, additional washing steps, or outright losses on final assay yields. Researchers report fewer purification headaches with our material, as contaminant removal becomes less of a major project bottleneck. Fewer side-products translate to quantifiable budget savings—a direct result, not a speculative claim.

We regularly support customers during tech transfer, ensuring that their analytical protocols line up with our in-house methods. Open data exchange, including spectral overlays and reference impurity profiles, helps medicinal chemists and process teams resolve issues early. The close, iterative loop between plant chemists and R&D teams means application successes feed back into production decisions—driving deeper quality.

Calibrated for Today’s Synthetic Routes

This molecule aligns with the rising complexity of modern drug candidates and advanced research programs. Traditional approaches targeting highly functionalized amino acid analogues stalled with generic intermediates; our product moves these programs forward. Building in rigid stereocontrol, especially for those addressing difficult sp^3-rich fragment assembly or new macrocyclic platforms, demands a component without the hidden costs of racemization or mixed chiral output.

Partners in both pharma and specialty chemicals appreciate that our material allows smoother workflow integration. Rather than adapting their reaction, protection, or deprotection strategies to match variable-quality starting materials, they build out from a standard that eliminates one of the biggest technical risks. Advanced projects, be they structure–activity series, C–C fragment elaborations, or exploratory synthetic campaigns, all benefit from the direct tie between our process and their final product specifications.

Process chemists and production supervisors routinely emphasize lower overhead costs after adopting our compound. Less downtime chasing impurity issues translates into more productive development and earlier delivery schedules for both research and commercial supply chains.

Environmental Safety and Regulatory Practices

We integrate environmental controls at every synthesis stage, minimizing residual solvents and ensuring that only drain-safe and air-compliant operations exit the plant. Proper solvent recovery based on detailed analysis is essential, as unchecked loss of terephthalic and benzoyl residues drives regulatory scrutiny. Our waste stream is monitored and sampled beyond local guidelines, keeping both our staff and the surrounding community protected.

Material handling and safety steps are always communicated to direct end-users along with every lot. Our transparent record-keeping and batch archiving mean researchers have full traceability from starting materials to finished product. Auditors, whether from regulatory agencies or global clients, see matched documentation and internal compliance reviews that verify both quality and safety records.

Continuous Improvement Built from User Experience

Customer collaboration guides both process refinement and new analytical investments. When synthetic chemists signal rising needs for increased throughput or faster turnaround on large-volume delivery, we have the operational flexibility to adjust production schedules. Scaling up, validating and re-validating process steps, and openly sharing analytical trends with users drive the compound’s evolving strengths.

Feedback loops from bench scientists directly inform process upgrades. Early feedback indicated a challenge with minor benzoyl contaminants in the workup phase; multiple filtration and recrystallization tests ultimately tightened both final color and purity. Subsequent batches showed more reproducible melting ranges, which clients confirmed on arrival—no unnecessary requalification delaying their timelines.

Whether a group struggles with program bottlenecks or faces regulatory hurdles from starting material quality, we see it as our challenge too. Earning trust has never rested on volume alone—it grows with each project that moves ahead faster and cleaner, anchored by materials that deliver.

In a World Demanding More From Chiral Building Blocks

In the context of crowded discovery pipelines and shorter cycle times, reliable stereochemically-defined intermediates like (4S,5R)-3-Benzoyl-2,2-Dimethyl-4-Phenyloxazolidine-5-Carboxylic Acid drive tangible program advantages. Bridging synthetic complexity with operational simplicity only happens through the kind of hands-on, plant-based refinement that focuses on every batch, every time, every handoff.

Offering both the flexibility demanded by evolving discovery science and the solid foundation preferred by process engineering teams, this product reflects the intersection of years spent running, analyzing, and adjusting chemistry in the real world. From lab benchtop to pilot plant, researchers discover a surprising degree of relief as the number of variables to manage decreases—leaving them free to do what matters most: design, synthesize, and advance the next wave of chemical innovation.